Southern Cross Equities biotech analyst Stuart Roberts was behind the recent DNA, Devices and Dealers conference in Sydney. Here, he explains his passion for hanging out with biotech's true believers. [ + ]

What are the odds that Australians' precious nest eggs be used to invest in something as risky as biotech? Well guess what -- it's already happening, and governments face pressure to free up more superannuation funds, writes Ruth Beran. [ + ]

Expat Kiwi Simon Moroney knows all too well the vagaries of the share market through his listed German biotech company, MorphoSys, writes Fiona Rotherham. [ + ]

The Australian science industry has grown in the last few years. While the progress being made by Australian industries is impressive, there are still many ways in which to improve efficiency and marketability on a global market

University of Sydney spin-out company Medsaic has developed a proprietary technology, DotScan, which can be used to diagnose haematological malignancies, solid tissue tumours and autoimmune diseases

A new biotechnology incubator facility due to open in Queensland by the end of this year is calling for companies seeking mentoring and support. [ + ]

Cochlear boss Chris Roberts has spent 30 years at Australia's leading device companies -- but that doesn't mean he has stopped learning, as Helen Schuller discovers. [ + ]

Dump the drugs? No -- but dump the stigma of 'biotech' and look for proper recognition from the investment community, writes CogState CEO Peter Bick. [ + ]

You may be strapped for time, but a poorly-chosen new recruit could set you back even further, writes Jeremy Wurm. [ + ]

If your brain disengages when you read the word 'ethics', perhaps you'd better switch it on again, writes Iain Scott -- there's a lot you haven't heard on the subject. [ + ]

In an outcome recalling one of Australia's greatest scientific achievements, researchers from the CRC for Clean Power from Lignite (CRC CPL) have designed and commercialised a revolutionary instrument

A University at Buffalo scientist created a stir in 2003 when he announced a much faster, more precise and far less expensive method of obtaining nuclear magnetic resonance (NMR) data to map a protein's atomic structure

Ann Uldridge explains the reasoning behind a new group for women in the biotechnology industry. [ + ]

Scientists, industry and government are doing their bit to develop the Australian biotechnology industry, writes Peter Andrews -- so where are the investors? [ + ]

Australian Biotechnology News editor-in-chief Iain Scott spoke with renowned industry analyst Cynthia Robbins-Roth about what it will take to keep biotech alive. [ + ]